[Diagnosis and Treatment of MSI-H Cancer in the Urological Malignancy].
In May 2017, the Food and DrugAdministration granted accelerated approval to pembrolizumab for microsatellite instability- high(MSI-H)or deficient mismatch repair(dMMR)solid tumors irrespective to tumor origins. Lynch syndrome is one of the diseases causingMSI -H tumor, however some sporadic cancers have MSI-H. We focus on the frequency of Lynch syndrome and sporadic MSI-H tumor in urological cancer.